Proteon logo     Print Page | Close Window

SEC Filings

S-1/A
PROTEON THERAPEUTICS INC filed this Form S-1/A on 10/07/2014
Entire Document
 

Table of Contents

    the timing and costs of developing PRT-201 for additional indications;
    the outcome, timing and costs of seeking regulatory approvals;
    the costs of commercialization activities for PRT-201 in radiocephalic AVFs and other indications if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
    subject to receipt of marketing approval, revenue received from commercial sales of PRT-201;
    the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;
    the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights, including royalty payments that we are obligated to pay to Johns Hopkins University pursuant to our assignment agreement related to PRT-201;
    the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and
    the extent to which we in-license or acquire other products and technologies.

    Cash Flows

        The following table summarizes our sources and uses of cash:

 
  Years Ended
December 31,
  Six Months
Ended June 30,
 
 
  2012   2013   2013   2014  
 
  (in thousands)
 

Net cash used in operating activities

  $ (8,234 ) $ (6,657 ) $ (3,386 ) $ (4,234 )

Net cash provided by investing activities

    7,382     2,727     4,294     (14,476 )

Net cash (used in) provided by financing activities

    (9 )   4,314         24,563  
                   

Net (decrease) increase in cash and cash equivalents

  $ (861 ) $ 384   $ 908   $ 5,853  
                   
                   

    Comparison of the Six Months Ended June 30, 2013 and 2014

        Net cash used in operating activities was $3.4 million during the six months ended June 30, 2013 compared to $4.2 million during the six months ended June 30, 2014. The increase of $0.8 million in cash used in operating activities in the first six months of 2014 was primarily driven by an increase in our operating expenses of $1.0 million, offset by a decrease in working capital balances and an increase in non-cash operating expenses of $0.2 million as compared to the first six months of 2013.

        Net cash provided by investing activities was $4.3 million during the six months ended June 30, 2013 compared to a use of cash of $14.5 million during the six months ended June 30, 2014. The increase in cash used in investing activities of $18.8 million in the first six months of 2014 was driven by an increase in the purchases of available for sale investments of $15.3 million combined with a decrease in maturities of short term investments of $3.5 million compared to the first six months of 2013.

        There was no net cash provided by financing activities during the six months ended June 30, 2013 compared to $24.6 million during the first six months of 2014. This increase was a result of the Series D convertible preferred stock issuance in May 2014.

    Comparison of the Years Ended December 31, 2012 and 2013

        Net cash used in operating activities was $8.2 million for the year ended December 31, 2012 compared to $6.7 million for the year ended December 31, 2013. The decrease of $1.6 million in cash used in operating activities was primarily driven by a $0.9 million decrease in our operating expenses and the

77